Natuzzi (NYSE:NTZ) reported quarterly losses of €(0.02) per share. This is a 100 percent decrease over losses of €(0.01) per share from the same period last year. The company reported €116.90 million in sales this quarter. This is a 10.48 percent decrease over sales of €130.58 million the same period last year.
Autolus Therapeutics’ CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort
Autolus Therapeutics plc (NASDAQ:AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell…
